INTRODUCTION
The innate immune response functions as both the first line of defense against pathogens and also as the initiating trigger for adaptive immunity (Iwasaki and Medzhitov, 2010; Janeway, 1989; Medzhitov et al., 1997) . Activation of dendritic cells (DCs), the professional antigen-presenting cells, drives T cell activation. These essential functions notwithstanding, the magnitude of DC activation must be precisely controlled. Unrestrained DC responses can lead to pathological conditions characterized by overreactive immune responses, such as allergy, autoimmunity, and chronic inflammatory diseases (Coombes and Powrie, 2008; Lambrecht and Hammad, 2010) . A priori, the induction of T cell activation must be coupled to a homeostatic negative feedback mechanism that limits the function of DCs. Such a mechanism would still allow T cell activation and initiation of adaptive immunity by DCs, yet enable T cells, once activated, to signal back to DCs and restrain further stimulation of the immune response.
Receptor tyrosine kinases (RTKs) of the TAM family, Axl and Mertk, are pleiotropic negative regulators of Toll-like receptor (TLR) and cytokine receptor signaling in DCs (Rothlin et al., 2007) . Two ligands for the TAM receptors, Protein S (Pros1) and Gas6, have been identified by in vitro approaches (Stitt et al., 1995) . Although the source of the ligands that activate TAM receptors in DCs in vivo is unknown, T cell-dependent activation of TAM receptors would allow for an inflammatory response in DCs upon initial pathogen encounter, followed by downregulation of this response once antigen presentation and T cell activation have occurred. Therefore, we considered the possibility that T cells might be an important source of TAM ligands. Here, we show that Pros1 was expressed by mouse and human activated T cells and inhibited DC function. Although Pros1 is well known to function as an essential anticoagulant where its action is TAM-independent (BurstynCohen et al., 2009; Dahlbä ck, 2007) , we reveal an antiinflammatory function of T cell-derived Pros1 as the in vivo TAM ligand. Our results also reveal that this T cell-derived Pros1-DC TAM signaling axis is an indispensable, evolutionarily conserved, homeostatic feedback mechanism by which adaptive immunity controls the magnitude of the innate immune response.
RESULTS

Activated T Cells Express Pros1
To test the hypothesis that activated T cells constitute a relevant immunological source of Pros1, we first measured Pros1 expression upon antigen presentation in vitro. Activation of OT-II transgenic CD4 + T cells upon incubation with bone marrow (BM)-DCs in the presence of ovalbumin (OVA) in vitro led to the detection of Pros1 on activated T cells ( Figure 1A ). Next, we generated a mouse where Pros1 expression was genetically ablated specifically in T cells. Mice homozygous for ''floxed'' Pros1 alleles (Burstyn-Cohen et al., 2009) were crossed with mice expressing CRE recombinase under the control of the Cd4 promoter. Although complete Pros1-deficient mice die in utero due to fulminant coagulopathy (Burstyn-Cohen et al., 2009; Saller et al., 2009) Figure 1B ). Pros1 expression was detected in activated antigen-specific T cells in vivo ( Figure 1B) . Finally, direct activation of isolated murine splenic CD4 + T cells via anti-CD3 and anti-CD28 stimulation led to the upregulation of Pros1 messenger RNA (mRNA) ( Figure 1C ) and protein ( Figure 1D ). Consistent with the genetic ablation of Pros1 in T cells, this upregulation was undetectable in in vitro activated T cells from Pros1
Cd4-Cre + mice (Figure S1 ). Resting CD4 + T cells did not express Pros1 ( Figure 1D ).
Similar results were obtained by using T cells from Pros1
flox/flox
Lck-Cre + mice. Neither resting nor activated T cells expressed Gas6 (data not shown). Taken together, these results indicate that T cells, activated in an antigen-specific manner, express Pros1.
Deficiency of Pros1 in T Cells Leads to Accelerated Disease Onset in a Model of Induced Colitis
The transfer of CD4 + CD25 À CD45RB hi cells into Rag1 À/À mice results in the induction of colitis, a disease dependent on microbiota and triggered by antigen-specific DCs (Coombes and Powrie, 2008; Feng et al., 2010 naive T cells led to a substantial acceleration of disease onset, as indicated by higher colonoscopy scores ( Figure 2A ; Figure S2) . Increased numbers of interferon-g (IFN-g) and interleukin-17A (IL-17A) expressing T cells were detected in the mesenteric lymph nodes of Pros1 À/À CD4 + CD25 À CD45RB hi recipients, relative to the control CD4 + CD25 À CD45RB hi recipients ( Figure 2B-2D) . Similarly, higher numbers of IL-17A expressing T cells were detected in the lamina propria of mice receiving Pros1 À/À naive T cells ( Figure 2E ). These results indicate that Pros1 expression in T cells limits pathological inflammation.
T Cell-Derived Pros1 Limits DC Activation Next, we directly tested whether T cell-derived Pros1 regulates DC activation in vivo. Control and Pros1-deficient OT-II CD45.2 + CD4 + T cells were transferred into CD45.1 + recipient mice, which were subsequently immunized with OVA-LPS-IFA in their footpads. Remarkably, the loss of Pros1 in antigen-specific T cells resulted in a significant increase in the population of activated DCs, as detected by the expression of the costimulatory molecules CD86 and CD40, in the draining lymph node ( Figure 3A) . Similarly, we detected an enhancement in the activation of DCs when Pros1 flox/flox Cd4-Cre + mice were directly immunized with OVA-LPS-IFA ( Figure S2 ). Given these findings, we tested the ability of T cell-derived Pros1 to directly regulate the magnitude of DC activation upon antigen presentation in vitro. We cocultured CD4 + CD25 À cells obtained from either Figure 3B ). Furthermore, tumor necrosis factor-a (TNF-a) and IL-6 production were also increased in the absence of T cell-derived Pros1 ( Figures 3C and 3D) . Importantly, Pros1 produced by activated T cells did not exert an autocrine effect: There were no significant differences in the expression of activation markers, production of cytokines, and proliferation between control (Pros1 flox/flox Cd4-Cre À or Pros1 wt/wt Cd4-Cre + ) and Pros1-deficient T cells when they were activated in vitro with anti-CD3 and anti-CD28 ( Figure S3 ). In agreement with the increased activation of DCs in the absence of T cell-derived Pros1, Pros1 flox/flox Cd4-Cre + mice immunized with OVA-LPS-IFA developed larger lymph nodes in comparison to control mice, primarily due to an expansion of T cells ( Figure S2 ). Furthermore, we detected an increase in the proliferation of Pros1 À/À CD4 + T cells isolated 10 d.p.i. when they were restimulated with OVA in vitro, as well as higher amounts of IL-2 in the culture supernatant ( Figure S2 ). Similarly, when control or Pros1 À/À OT-II T cells were transferred into mice that were subsequently immunized with OVA-LPS-IFA, we detected significantly higher numbers of transferred OT-II T cells and increased cellularity of the draining lymph nodes in those mice that received Pros1 deficient antigen-specific T cells ( Figure S2 ). These findings are consistent with an increase in the number of antigen-specific T cells generated in the absence of T cell-derived Pros1.
To further confirm whether T cells are a relevant source of Pros1 for immunomodulation, we compared the immune response of control and Pros1 flox/flox Cd4-Cre + mice to T-dependent and T-independent antigens. Pros1 flox/flox Cd4-Cre + mice developed significantly higher titers of antitrinitrophenyl (TNP) immunoglobulin G1 (IgG1) in comparison to control mice upon immunization with the hapten TNP linked to keyhole limpet haemocyanin (KLH), a T-dependent antigen ( Figure 4A ). Conversely, no differences between Pros1 flox/flox Cd4-Cre + and control mice were detected upon immunization with the T-independent antigen TNP-Ficoll ( Figure 4B ). Interestingly, by 9 months of age, Pros1 flox/flox Cd4-Cre + mice showed a spontaneous expansion of CD4 + CD44 hi CD62L À cells ( Figure S4 ). However, autoantibodies, such as anti-DNA antibodies, were not detectable in 6-to 9-month-old mice ( Figure S4 ). Taken together, the above results indicate that Pros1 expression in activated antigen-specific T cells is required for the homeostatic regulation of the magnitude of DC activation, thus ensuring a physiological immune response.
T Cell-Derived Pros1 Acts Locally to Inhibit DC Activation through TAM Signaling Pros1 carries an N-terminal g-carboxyglutamic acid (GLA)-rich domain that allows it to bind to cell membranes containing the negatively charged phospholipid, phosphatidylserine (PtdSer). Binding of Pros1 to PtdSer is an essential feature of its biological activity (Nyberg et al., 1997) . Interestingly, PtdSer is transiently exposed on the outer leaflet of the plasma membrane of activated T cells ( Figure S5 ; Fischer et al., 2006) . This feature prompted us to test whether T cell-derived Pros1 functioned locally, at the interface of DC-T cell interaction, by Immunity T Cell-Derived Protein S Regulates DC Activation physically separating DC and T cells with a transwell system. To this end, we utilized T cells that had been prestimulated in vitro with anti-CD3 and anti-CD28 to bypass the need for DC-T cell contact to induce Pros1 expression in the T cells. Splenic CD4 + CD25 À T cells were activated in vitro and were then cocultured with BM-DCs in the presence of several different agonists of pattern recognition receptors. BM-DCs expressed higher amounts of CD86 and CD40 in response to poly I:C when cocultured with Pros1-deficient versus control T cells ( Figure S5 ). Furthermore, the production of many different cytokines (TNF-a, IL-6, IFN-b) was significantly higher when BM-DCs were activated in the presence of Pros1
T cells than control T cells ( Figure S5 ). Similarly, the activation of BM-DCs with CpG-A was also higher when DCs were cocultured with Pros1-deficient T cells than with control T cells (Figure S5) . Addition of recombinant Pros1 to the cocultures rescued the ability of activated Pros1 À/À T cells to regulate DC function ( Figure S6 ). Next, we utilized the transwell system to physically separate in vitro activated T cells from BM-DCs. Interestingly, no differences in the expression of activation markers (e.g., costimulatory molecules) were detected when BM-DCs were cultured across the transwell with either control or Pros1 À/À T cells ( Figure 5A ). These results suggest that Pros1-TAM signaling is not engaged in the presence of a Immunity T Cell-Derived Protein S Regulates DC Activation permeable but physical barrier. Binding to exposed PtdSer on activated T cells might restrict Pros1 to the T cell surface, accounting for this localized function. Because Annexin V has been shown to efficiently compete with Pros1 for PtdSer binding (Anderson et al., 2003; Webb et al., 2002) , we compared the activation of BM-DCs cocultured with activated T cells in the absence or presence of Annexin V. Addition of Annexin V to the coculture led to a significant enhancement of the expression of CD86 and CD40 by BM-DCs upon poly I:C stimulation in wild-type (WT) but not Pros1-deficient T cells (Figure 5B ; Figure S6 ). These results indicate that Pros1 binding to PtdSer is necessary for its immunomodulatory effect. We also tested whether the loss of Axl and Mertk signaling in DCs phenocopied the loss of Pros1 in T cells by using the in vitro antigen-presentation assay. When cocultured with Pros1-expressing OT-II T cells, BM-DCs lacking both Axl and Mertk (Axl
Mertk
À/À ) expressed substantially higher amounts of costimulatory molecules, relative to WT BM-DCs ( Figure 5C ). These results indicate that the loss of Axl and Mertk renders DCs refractory to T cell-derived Pros1-mediated regulation. TAM signaling regulates the degree of DC activation through the induction of Socs, which in turn leads to reduction of NF-kB activity (Rothlin et al., 2007) . The use of Pros1-deficient T cells in the T cell:DC coculture system led to the reduced induction of Socs3, increased IkBa degradation, and increased p65 NF-kB phosphorylation in BM-DCs in comparison to control T cells ( Figures 5D-5F ). Together, all of these data demonstrate that T cell-derived Pros1 functions locally at the DC-T cell interface and engages TAM signaling within DCs to limit their activation.
PROS1 Expression and Function Are Conserved in Humans
To test whether human T cells express PROS1, human naive CD4 + T cells were isolated by negative selection from human peripheral blood mononuclear cells (PBMCs) and stimulated with anti-CD3 plus anti-CD28. In vitro activation of human CD4 + T cells led to a significant induction of PROS1 mRNA as well as PROS1 expression on the cell surface (Figures 6A and 6B). We also compared PROS1 expression in the interfollicular T cell area of reactive versus nonreactive human lymph nodes. Sections from nonmalignant human lymph nodes classified by histopathological analyses as nonreactive (n = 6) or reactive (n = 6) were stained with anti-CD3 and anti-PROS1 antibodies and counterstained with hematoxylin. PROS1 staining was positive in the CD3 + T cell area of reactive lymph nodes with no expression detectable in nonreactive lymph nodes ( Figure 6C ).
To explore whether human T cell-derived PROS1 indeed functions in regulating the degree of DC activation, we performed mixed lymphocyte reactions (MLRs). Monocyte-derived DCs and naive T cells were isolated from different donors and cocultured for 5 days. Monocyte-derived DCs express both AXL and MERTK, whereas activated T cells express PROS1 in the MLR (data not shown). In agreement with a regulatory role for PROS1, the neutralization of PROS1 with an anti-PROS1 antibody led to a significant increase in CD86 and CD40 expression in human monocyte-derived DCs (Figures 6D and 6E) .
To test whether the loss of function of PROS1 is associated with pathological inflammation in humans, we extended our studies to patients with Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn's Disease. PROS1 Immunity T Cell-Derived Protein S Regulates DC Activation amounts are measured routinely from patient plasma for the diagnosis of PROS1 deficiencies. Interestingly, patients with active IBD frequently showed lower amounts of plasma PROS1 relative to healthy controls ( Figure 6F ). More than 200 germline mutations in the PROS1 gene have been described. Type I deficiencies, characterized by reduced PROS1 amounts, are associated with mutations within the coding region (Gandrille et al., 2000; García de Frutos et al., 2007) . Therefore, for Type I deficiencies, the plasma concentration of PROS1 (produced by hepatocytes and endothelial cells) is likely to function as a surrogate for the amount of PROS1 produced by other cellular sources, including T cells. Future studies directly measuring T cell-derived PROS1 will further validate this hypothesis.
Collectively, these results indicate that this anti-inflammatory pathway is present in humans and functions in maintaining immune homeostasis.
DISCUSSION
Our results reveal a hitherto unknown indispensable, negative feedback mechanism by which activated T cells restrain DC activation and, thereby, regulate the overall magnitude of the immune response. Following initial DC activation and antigen presentation, T cells are activated, leading to the induction of Pros1. Pros1 engages the anti-inflammatory TAM receptor tyrosine kinase signaling pathway in DCs. This enables activated T cells to report back to DCs and restrain further stimulation of the overall immune response. This feedback mechanism is Immunity T Cell-Derived Protein S Regulates DC Activation essential for maintaining the physiological balance of immune activation capable of host defense yet avoiding exacerbated inflammation. The absence of this ''immunological brake'' leads to pathological inflammation and chronic inflammatory diseases, such as colitis. Importantly, Pros1-TAM signaling is not redundant with respect to other negative regulators. Although Pros1 is a secreted protein, its immunoregulatory function is dependent on its binding to the T cell-surface associated PtdSer, thereby restricting Pros1 function to DC-T cell interface. Because cognate DC-T cell interactions are antigen-specific, this property of Pros1 presumably results in an antigen-specific negative regulatory function. Whether this feature makes Pros1 distinct from other known negative regulators of DC activation, such as IL-10 (Banchereau et al., 2012), and prevents compensation remains unknown. Future studies focused on Pros1 function in a variety of immunological settings and its integration with known regulatory pathways will provide a more comprehensive understanding of mechanisms through which the adaptive immune system, once engaged, regulates the magnitude of the innate immune response and how overall immune homeostasis is maintained. Pros1, produced by hepatocytes and endothelial cells, is found in large amounts in the blood (Burstyn-Cohen et al., 2009 (D and E) CD86 and CD40 expression were measured on CD11c + cells at day 5. Representative histograms (left) and independent data with at least three independent samples per group (right) are shown. Each experiment was repeated at least twice employing three to five different donors.
(F) Percentage of total PROS1 in healthy controls (n = 9) and IBD patients (n = 11). Horizontal lines indicate the mean in each group. Total PROS1 was determined using automated latex immunoassay methodology and normalized to an average value of PROS1 from a pool of healthy donors. *p < 0.05, **p < 0.01, ***p < 0.01. The loss of these distinct functions likely accounts for the autoimmunity in TAM triple-deficient mice. Thus, the combinatorial deletion of the two ligands might be required to recapitulate the spontaneous autoimmunity characteristic of TAM tripledeficient mice. Our results reveal the hitherto unknown function of Pros1 as an endogenous anti-inflammatory protein and a key regulator of immune homeostasis. The most well-established activity of Pros1 to date is TAM-independent, in which it functions as an anticoagulant (Gandrille et al., 2000) . In fact, Smiley et al. reported the expression of Pros1 in activated T cells yet ascribed this to an anticoagulant role of T cells (Smiley et al., 1997) . Is the duality of Pros1 function relevant in physiological or pathological settings? Chronic inflammatory and autoimmune diseases have been described anecdotally, yet repeatedly, in patients with low circulating amounts of PROS1 (Aadland et al., 1992; Koutroubakis et al., 2000; Suh et al., 2010; Zezos et al., 2007) . Additionally, diseases, such as IBD, are often concurrent with thrombotic events (Grainge et al., 2010) . The discovery of the novel immunomodulatory function of Pros1 might provide a unifying molecular explanation for these two clinical features of IBD. The association of reduced PROS1 with IBD supports the notion that there might be a causal link. However, thrombotic events can directly lead to inflammation, and our present results do not rule out an association between IBD and a subset of patients with PROS1 loss limited to the plasma. On the other hand, we are also likely to miss patients with T cell-specific loss of PROS1 because T cells do not contribute to the plasma concentration of PROS1. Nevertheless, the association is intriguing, and dedicated efforts focused on measuring T cell-derived PROS1 might causally link PROS1 deficiencies with the development and progression of autoimmune or chronic inflammatory diseases, as well as reveal PROS1 as a useful biomarker for minimally invasive diagnosis and prognosis of IBD in the future. were obtained from Jackson Laboratory. All mice were bred at Yale University animal facility. All mice were specific-pathogen free, maintained under a strict 12 hr light cycle (lights on at 7:00 a.m. and off at 7:00 p.m.), and given a regular chow diet. All experimental procedures were approved by Yale IACUC.
Antibodies
The following anti-mouse antibodies were purchased from BD-Biosciences, eBioscience, Santa Cruz or BioLegend (USA), as conjugated to FITC, PE, PE-Cy5, PerCP-Cy5.5, APC-Cy7, Alexa Fluor 700, PE-Cy7, Pacific Blue, or APC: CD3 (145-2C11), CD4 (GK1.5, L3T4, RM4-5), CD8 (53-6. As a secondary antibody, DyLight 649 donkey anti-rabbit IgG (Poly4064) was used. Monoclonal antibody against human GLA residues (American Diagnostica) was used to immunoprecipitate GLA containing proteins from serum.
The following anti-human antibodies were purchased from BD-Biosciences or BioLegend (USA), conjugated to Alexa Fluor 488, FITC, APC-Cy7, APC, PE, Pacific Blue: CD2 (TS1/8), CD69 (FN50), CD3 (UCHT1), CD4 (RPA-T4), CD11c (3.9), CD11b (MI/70), CD40 (5C3), CD86 (IT2.2), and PROS1 (PS7).
Flow Cytometry Analysis
For standard stainings, cells were harvested and washed once with PBS and then blocked with Fc-block (BD-Bioscience) for at least 10 min in PBS-2% FBS. Cells were washed again and incubated with the respective cocktail of antibodies for 30 min on ice. Antibody cocktails were prepared in PBS-2% FBS. 7ADD was also included to gate on live cells. After the last wash, cells were acquired on a FACSCalibur, LSR-II (BD) or Stratedigm S1000EX (Stratedigm).
For Pros1 staining, after cells were collected and washed, they were fixed with cold acetone (À20 C) for 5 min and washed three times with PBS to discard all remaining acetone. After washing, cells were blocked with PBS-3% BSA for 30 min on ice. They were washed again and anti-Pros1 (H90) (Santa Cruz Biotechnology, USA) was added at 1 mg per 1 3 10 6 of cells in PBS-3% BSA. Cells were incubated for 1 hr on ice and then washed twice. The secondary DyLight 649 donkey anti-rabbit (Biolegend, USA) was added and incubated for 30 min on ice. After the final wash, samples were acquired on a FACSCalibur or LSR-II (BD). All the directly conjugated antibodies used together with Pros1 staining were tested for acetone fixation.
RT-qPCR
At the indicated time points, cells were harvested and washed, and RNA was isolated with RNeasy mini kit (QIAGEN, USA) following the manufacturer's instructions. Reverse transcription was performed with RT Superscript III (Invitrogen) or iScript cDNA Synthesis kit (BIO-RAD). qPCR reactions were performed on Stratagene Mx3000 System with KAPA SYBR Fast qPCR kit (KAPABIOSYSTEM). The reactions were normalized to housekeeping gene and the specificity of the amplified products was checked by dissociation curves. Primers used in this paper are listed in Table S1 . 
BMDC Differentiation
Bone marrow dendritic cells (BMDC) were obtained from WT or Axl
) mice following a standard protocol for differentiation. Briefly for BMDC, bone marrow progenitors were collected from the femurs of the indicated mice and 7-10 3 10 6 cells were cultured in 100 3 20 mm nontreated cell culture plates in 10 ml of enriched medium, RPMI 1640 plus 10% fetal bovine serum (FBS), 1% penicillin and streptomycin and supplemented with 20 ng/mL of recombinant GM-CSF (Peprotech, USA). At days 3 and 5 of cell culture, 10 and 5 ml of enriched media were added, respectively. On day 6, BMDCs were harvested and 90%, on average, of harvested cells were positive for CD11c. stimulated with 30 mg/mL of Poly I:C or 0.5 mM CpG-A (Invivogen, USA) in serum-free medium supplemented with 1/10 of conditioned media from HEK293 expressing recombinant murine Protein S (Prasad et al., 2006) .
Antigen Presentation Assays
Competitive Annexin V and Transwell Assay T cell/BMDC coculture was performed as described above. For competitive Annexin V assay, 10 mg/mL of recombinant Annexin V (BD-Bioscience, USA) was added to the T cell culture 1 hr prior to the addition of BMDCs. BMDCs were added onto preactivated T cells that have been incubated with Annexin V and the protocol was continued as was previously described. For the transwell assay, T cells were preactivated on the bottom portion of the transwell for 4 hr and then DCs were added on top of transwell membrane (0.4 mm, Corning, USA). As a control, DCs were also added at the bottom, directly onto preactivated T cells. The activation of DCs was performed as described above. ) mice and transferred intraperitoneally (i.p.) into Rag1 À/À mice (4 3 10 5 cells/mouse). Colonoscopy was performed in a blinded fashion for colitis scoring via the Coloview system (Karl Storz, Germany). In brief, colitis scoring was based on granularity of mucosal surface, stool consistence, vascular pattern, translucency of the colon, and fibrin visible (0-3 points for each). Mice were sacrificed about 6-8 weeks after the transfer, and cells isolated from the colon and mesenteric lymph nodes were analyzed for IFN-g and IL-17A-producing CD4 cells.
Immunization Protocols
Generation of Human Monocyte-Derived DC
We plated 1 3 10 8 PBMCs in 8 ml of RPMI 1640 plus 2% of human serum in 75 cm 2 cell culture flask and incubated at 37 C with 5% CO2 for 60 min for monocyte adherence. After the incubation period, the nonadherent cells were removed by washing four times with 6-10 ml of PBS. The adherent cells were cultured in 8 ml RPMI-1640 10% FCS containing 300 U/mL of IL-4 (R&D), 450 U/mL of GM-CSF (R&D) at 37 C, and 5% CO2. Cytokine supplementation was performed again on day 3 by adding 4 ml RPMI 1640 10% FCS containing 900 U/mL of IL-4, 1,350 U/mL GM-CSF. Monocyte-derived DCs were harvested on day 7.
PROS1 Expression in Human T Cells
Human naive CD4 T cells were obtained from PBMCs with EasySep human naive CD4 + T cell enrichment kit (STEMCELL Technologies). We cultured 0.5 to 1 3 10 5 purified naive CD4 + cells in presence (1:1 ratio) or absence of anti-human CD3/CD28 beads (Life Technologies) plus 3 ng/mL hIL-2 (Peprotech) in serum free medium (STEMCELL, USA) for 1 to 6 days. Cells were harvested daily and PROS1 expression was evaluated by qPCR with specific primers (Table S1 ) and anti-PROS1-FITC for surface staining by FACS.
Mixed Lymphocyte Reaction (MLR)
Human naive CD4 T cells were obtained by negative selection (STEMCELL Technologies) and cocultured with monocyte-derived DC, from a different donor, at 2:1 ratio for 5 days. For PROS1 blocking experiment, anti-PROS1 (PS7) antibody was added at day 4, and cells were harvested at day 5. CD40 and CD86 activation markers were measured on CD11c + cells by FACS. 
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